Elekta to elect a new board member?
This article was originally published in Clinica
Executive Summary
Jan Secher has been proposed as a member of Swedish firm Elekta's board. Mr Secher is currently president and CEO of industrial service provider Ferrostaal. He has also been operating partner of US private equity fund Apollo, and CEO of molecular diagnostics firm Clarient and SICPA, a specialist in security inks. Stockholm-based Elekta develops devices to treat cancer and brain disorder, including tools and planning systems for radiation therapy and radiosurgery.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.